Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics

Ka Lum¹, Taimur Bhatti¹, Silas Holland¹+2

• ¹Ka Lum, Ph.D., M.B.A., was the Head of Global Pricing & Market Access of Immunology, Infectious Diseases and Ophthalmology at Genentech, a member of the Roche Group. She holds a Bachelor of Science in Chemistry, a Bachelor of Arts in Applied Mathematics, a Doctor of Philosophy in Chemistry, and a Master of Business Administration from UC Berkeley. Taimur Bhatti, M.Sc., is an International Payer Strategy Leader in Infectious Diseases at Hoffmann-La Roche. He holds a Bachelor of Science in Biomedical Engineering from Duke University and a Master in Science in Health Economics/Pharmaceutical Sciences from the University of Toronto (Canada). Silas Holland, M.P.H., M.A., is a Director of Global Public Policy at Merck and Co., Inc. responsible for infectious disease global health policy, primarily focusing on antibiotics/antifungals. He holds a Bachelor of Science in Biology from Duke University and has postgraduate degrees in education (Loyola Marymount University) and public health (University of Pretoria, South Africa). Mark Guthrie, M.B.A., is the Global Pricing and Market Access Pipeline Head for Immunology, Infectious Disease and Ophthalmology at Genentech, a member of the Roche Group. He has a Master of Business Administration in Healthcare Management from the University of Baltimore and a Bachelor of Arts in Economics from Denison University. Stephanie Sassman is a Lifecycle Leader in Immunology at Genentech, a member of the Roche Group. She holds a Bachelor of Business Administration from the University of Texas at Austin.